ClinicalTrials.gg
TerminatedNCT06518915Updated Oct 20, 2026

Baroloop Multicenter Trial (Baroloop MCT)

An interventional study of baroloop system in Hypertension, Resistant to Conventional Therapy, sponsored by neuroloop GmbH. Terminated at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by neuroloop GmbH (part of B. Braun) · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Terminated following a device deficiency in 1 subject. Benefit-risk and development assessments did not support continuation within the planned framework. Root cause analysis pending.
Updated Oct 20, 2026Now TerminatedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn weather the baroloop system is safe and works to treat hypertension in adults that do not respond sufficiently to medication. The main questions it aims to answer are:

  • Is the baroloop device associated with any major medical problems including death?
  • Does the baroloop lower the blood pressure of study participants?

Participants will be implanted with the baroloop device. Afterwards they will visit the clinic after 14 days, 3 months, 6 months, 12 months, 18 months, and 24 months for adjustment of the device settings and/or other study related assessments. Participants will also be asked to answer questions regarding their quality of life.

02

Conditions studied

  • Hypertension, Resistant to Conventional Therapy
03

In context

Hypertension Resistant to Conventional Therapy

47 studies on the registry are indexed under Hypertension Resistant to Conventional Therapy; 3 are open to participants now.

This study's enrollment of 3 is below the median of 57 across 36 interventional studies indexed under Hypertension Resistant to Conventional Therapy.

Browse Hypertension Resistant to Conventional Therapy studies →

Lead sponsor

neuroloop GmbH is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older.
  2. Persistent office systolic blood pressure (SBP) ≥ 140 mm Hg and diastolic blood pressure (DBP) > 90 mm Hg on antihypertensive medicines on two visits separated by a minimum of four weeks.
  3. Mean 24-hour systolic ABPM ≥ 130 mm Hg and mean 24 hour diastolic ABPM ≥ 80 mm Hg conducted after direct observed therapy to confirm that antihypertensive medicines were taken as prescribed during the ABPM measurement.
  4. Stable drug regimen of 3 antihypertensive medicines consisting of a reninangiotensin blocker (ACE) or Angiotensin II Receptor Blocker (ARBs), a calcium channel blocker (CCB), and a diuretic for 4 weeks at treatment.
  5. Willingness and ability to comply with follow-up requirements.
  6. Signed .

Exclusion criteria

Exclusion Criteria:

  1. Any patient in whom access to the vagal nerve is limited by the size of the vagus (a size not compatible with the baroloop cuff).
  2. Any patient with a history of injury to the vagus nerve or its branches (e.g., the recurrent laryngeal nerve).
  3. Secondary causes of hypertension.
  4. Calculated \< 30 mL/min/1.73m2.
  5. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus ( > 10%).
  6. Requirement for chronic oxygen therapy or mechanical ventilation.
  7. Untreated (no CPAP therapy) sleep apnea (AHI > 15)
  8. Morbid obesity, defined as >40 kg/m2 or arm circumference 46 cm.
  9. Pacemaker and/or implantable defibrillators.
  10. History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening.
  11. Symptomatic carotid artery disease or > 70% occlusion of either carotid artery; any carotid malformation or lesion, a carotid bruit or other abnormal carotid sound.
  12. Prior surgery, radiation therapy or scarring in the neck in the region of the carotid artery (e.g., patients with a tracheostomy, extensive thymectomy or thyroid surgery).
  13. Limited mobility of the neck secondary to vertebral disease or prior vertebral surgery, including patients who wear a cervical support.
  14. History of heart failure ( class III-IV).
  15. Cardiac arrythmias (atrial fibrillation, atrial flutter, etc.) that require anticoagulation if the condition interferes with a consistent measurement of blood pressure.
  16. Unexplained syncope in the last 6 months.
  17. History of bleeding disorders, thrombocytopenia, hemophilia, or significant anemia ( (Hgb) \< 10 g/dl).
  18. Current anticoagulation therapy (excluding antiplatelet therapy with aspirin as a sole therapy).
  19. History of unresolved drug or alcohol use.
  20. Active treatment of a psychiatric ailment.
  21. of less than 12 months due to other disease.
  22. Subject has a condition that, in the opinion of the investigator, precludes participation, including willingness to comply, with all follow-up procedures.
  23. Participation in another clinical study for which follow-up is currently on-going.
  24. Women who are pregnant
  25. Resting heart rateof \< 45 beats/min s, confirmed at both baseline visits.
  26. Baroreflex failure or autonomic neuropathy
  27. Symptomatic, uncontrolled bradyarrhythmias
  28. Atrioventricular block of any grade
  29. Presence of a vagus stimulator
  30. Patients who are likely to require magnetic resonance imaging (MRI) of the cervical area
  31. Occupational exposure to high levels of non-ionizing radiation that may interfere with therapy
  32. Patients with a limited ability to read, understand and execute adjustment procedures (for example, persons suffering from dementia).
  33. Likely exposure to diathermy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Implantation of the baroloop device

    Device: baroloop system

Interventions

  • Devicebaroloop system

    Participants will have the baroloop device implanted for selective stimulation of the vagus nerve.

06

What researchers measure

Primary outcomes

  1. Safety of the baroloop device

    Composite Major Adverse Event (MAE) Rate including all-causes of death and all device or procedure-related serious adverse event

    Time frame: 6 months after initial stimulation

  2. Performance

    Change in mean 24-hour Systolic Ambulatory Blood Pressure (ABP) by ambulatory blood pressure monitoring

    Time frame: 6 months after initial stimulation

07

Study locations

4 sites
  • Clemenshospital Münster
    Münster, North Rhine-Westphalia 48153, Germany
  • Marienhaus Klinikum Mainz
    Mainz, Rhineland-Westphalia 55131, Germany
  • Städtisches Klinikum Dresden
    Dresden, Saxony 01067, Germany
  • UMC Utrecht
    Utrecht, Utrecht 3584 CX, Netherlands
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2024 to primary completion in Oct 2026, 28 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion May 2029 → Oct 2026 and completion Dec 2031 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2024
First posted
Jul 25, 2024
StartActual
May 22, 2024
Primary completionActual
Oct 1, 2026was May 2029
CompletionActual
Oct 1, 2026was Dec 2031
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Terminated following a device deficiency in 1 subject. Benefit-risk and development assessments did not support continuation within the planned framework. Root cause analysis pending.
changed Oct 20, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (1 Germany, 1 Netherlands)
  • Clemenshospital Münster · Münster, Germany
  • UMC Utrecht · Utrecht, Netherlands
Show 2 removed
  • Clemenshospital Münster · Münster, Germany
  • UMC Utrecht · Utrecht, Netherlands
Oct 20, 2026
Primary completion
May 2029→Oct 1, 2026 (actual)
Oct 20, 2026
Study completion
Dec 2031→Oct 1, 2026 (actual)
Oct 20, 2026
Enrollment
120 (estimated)→3 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Terminated
    Why stopped Terminated following a device deficiency in 1 subject. Benefit-risk and development assessments did not support continuation within the planned framework. Root cause analysis pending.
    2 sites added, 2 sites removed
    Show 2 added (1 Germany, 1 Netherlands)
    • Clemenshospital Münster · Münster, Germany
    • UMC Utrecht · Utrecht, Netherlands
    Show 2 removed
    • Clemenshospital Münster · Münster, Germany
    • UMC Utrecht · Utrecht, Netherlands
    Primary completion May 2029→Oct 1, 2026 (now actual)
    Study completion Dec 2031→Oct 1, 2026 (now actual)
    Enrollment 120 (estimated)→3 (actual)
    + 4 other changes: index terms, verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06518915
Lead sponsor
neuroloop GmbH
Collaborators
Avania
Responsible party
Sponsor
First posted
Jul 25, 2024
Start date
May 22, 2024
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion